Mark Feneley
Mr Mark Feneley was appointed as Senior Lecturer in Urological Oncological Surgery at the Institute of Urology, University College London in 2004, after one year as Consultant Urologist at University College London Hospitals (UCLH). He was formerly Clinical Lead for Urology (2008–2009), Lead for Urological Oncology (2003-2006), Lead for Bladder Cancer in the North Thames Cancer Network (2003-2009), and Lead Clinical Investigator in molecular biology at Prostate Cancer Research Centre, London, where his own research addressed diagnostic and prognostic molecular markers in early stage prostate cancer. He has served for two years on the Bladder Cancer NCRI Clinical Trials Group, and has specialist interest in diagnosis and treatment of non-muscle invasive bladder cancer.
Having experience in endocrine manipulation for prostate cancer, he has a particular research interest in androgen replacement therapy, androgen signalling in prostate cancer and its relation to inflammation in the prostate. Clinical practice includes clinical assessment and treatment of benign prostatic hyperplasia, including laser treatment (Greenlight ™, and Thulium 150 ™).
He is involved in the work of two charities, including The Society for the Study of Androgen Deficiency (Chairman and committee member), and Prostate UK (Medical Advisor). He has co-edited four textbooks, produced and edited several whole journal supplements, and published multiple book chapters and peer reviewed articles.
He is actively committed to undergraduate and postgraduate teaching, and is an internal examiner for the Royal Free and University College Medical School, and University of London. Prior to his appointment as Consultant at UCLH in 2003, he was a Consultant Urologist at Nottingham City Hospital (2000-2002) where he was also Director of Postgraduate Education. This followed a two year Clinical Post-Doctoral Fellowship in Urological Oncology, at the James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA (1998-2000), and higher urological training at St Bartholomew’s and Royal London Hospitals (1992-1998).
Medical qualifications and MD thesis on prostate cancer screening were gained at University of Cambridge in 1987 and 1996 respectively.
| Specialty : | Non muscle invasive bladder cancer, Photodynamic (fluorescent) cystoscopy for diagnosis and staging of bladder cancer, Endoscopic and intravesical treatments for bladder cancer including Intravesical chemotherapy, Intravesical immunotherapy, Intravesical electromotive drug administration with chemotherapy Greenlight ™ (HPS) laser photoselective vaporization of the prostate, Thulium 150 ™ laser vaporization and enucleation of the prostate |
| Research : | • Laser treatment for BPH • Diagnosis and treatment of bladder cancer, particularly intravesical therapy for non-muscle invasive cancer • Diagnostic and prognostic molecular markers in early stage prostate cancer • Inflammatory markers and androgen signalling in prostatic disease |
| Qualifications : | MD (Cantab), FRCS(Eng), FRCS(Urol) |
| GMC registration : | 3133220 |
| NHS hospital : | University College Hospital at Westmoreland Street |
| Tel (nhs) : | 020 3447 9422 |
| Fax (nhs) : | 020 3447 9303 |
| Email : | office@markfeneley.com |
| Private hospitals : | London Clinic, Princess Grace Hospital, Wellington Hospital, Harley St Clinic |
| Tel (private) : | 020 7486 3830 |
| Fax (private) : | 020 7486 3810 |
| Website : | www.markfeneley.com |
